Skip to main content
Erschienen in: International Journal of Colorectal Disease 8/2019

Open Access 28.06.2019 | Original Article

Risk factors for proctectomy in consecutive Crohn’s colitis surgical patients in a reference colorectal centre

verfasst von: Gisele Aaltonen, Monika Carpelan-Holmström, Ilona Keränen, Anna Lepistö

Erschienen in: International Journal of Colorectal Disease | Ausgabe 8/2019

Abstract

Purpose

Crohn’s colitis carries a risk for permanent stoma with extirpation of the rectum. We aimed to estimate the proctectomy rate and identify risk factors for proctectomy in patients with Crohn’s colitis.

Methods

For this study, we retrospectively reviewed data from consecutive patients with Crohn’s disease (CD) affecting the colon or anorectal region undergoing bowel resection in a reference colorectal centre between 2006 and 2016. The cumulative risk for proctectomy was calculated using the Kaplan-Meier curve. We used univariate and multivariate logistic regression analyses to determine independent risk factors for proctectomy. Outcomes after proctectomy concerning reoperation frequency and perineal wound healing are also described.

Results

In total, this study included 125 patients. Proctectomy was performed in 36 patients (28.8%), of whom 14 patients (38.9%) experienced perineal wound healing problems. The rates of proctectomy were 5.6% and 32.0% 10 and 20 years after CD diagnosis, respectively. Female gender (odds ratio (OR) 3.375, 95% confidence interval (CI) 1.304–8.733, P = 0.012), disease duration (OR 1.067, 95% CI 1.011–1.126, P = 0.018) and history of perianal disease (OR 3.160, 95% CI 1.215–8.219, P = 0.018) were independent risk factors for a proctectomy procedure, whereas thiopurine medication (OR 0.170, 95% CI 0.060–0.486, P = 0.001) was an independent protective factor for proctectomy.

Conclusions

The duration of Crohn’s disease, female gender and a history of perianal disease were significant risk factors for a proctectomy procedure. Future research should examine whether immunosuppressive and biological medications reduce the risk for proctectomy.
Hinweise

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

According to population-based studies, the incidence of Crohn’s colitis has increased in recent decades [1, 2]. It is estimated that more than 60% of Crohn’s disease (CD) patients have colonic involvement. Isolated Crohn’s colitis is found in 20% of patients suffering from CD, but ileocolonic involvement is more common [3]. CD of the colon or anorectal region is associated with a risk for definitive stoma requiring extirpation of the rectum. Many patients affected by this type of CD fear permanent stoma. Temporary stoma formation may be used to control disease while allowing for the recovery of the bowel distal to the covering stoma. However, a recent meta-analysis has shown that only 34% of CD patients with temporary stoma will ever have their stoma closed and only 16% of these patients will improve without undergoing a new stoma construction [4]. Furthermore, previous studies reported proctectomy rates of 20% in Crohn’s colitis patients [5, 6].
One randomized controlled trial described a diminished need for perianal disease surgery in patients treated with thiopurine medication [7]. In addition, biological medications appear to improve perianal disease [810]. However, previous studies did not specifically evaluate the effect of CD medications in preventing proctectomy and further investigations are needed.
Construction of end colostomy with preservation of part of the large bowel increased postoperative CD recurrence in Crohn’s colitis patients according to previous studies [11, 12]. Concomitant terminal ileum disease was also described as a risk factor for postoperative CD recurrence in Crohn’s colitis patients [13, 14].
Our study aimed to determine the proctectomy rate and identify the risk factors for proctectomy in surgical Crohn’s colitis patients. Furthermore, we evaluated the frequency of reoperations and delayed perineal wound healing after proctectomy.

Material and methods

Clinical records from all patients with colonic or anorectal CD undergoing bowel resection in a reference colorectal centre between 2006 and 2016 were retrospectively reviewed for this study. We excluded patients with disease limited to the small bowel or terminal ileum without involvement of the colon or anorectal region. We collected data on patient age, gender, date of CD diagnosis, history of perianal disease and terminal ileum disease, as well as the use of corticosteroids, thiopurine and biological medications. As preoperative medication, we considered the medication in use for the last 6 months before surgery. The index operation was either proctectomy or other bowel resection in patients not referred for proctectomy during the study period. Proctectomy date, indication, approach and the frequency of perineal complications and reoperations during follow-up were also recorded. Reoperation was defined as the need for a new bowel resection due to recurrent disease. CD duration was calculated from the date of diagnosis until the date of the index operation.
The Kaplan-Meier curve was used to calculate the cumulative risk for proctectomy from CD diagnosis until the end of follow-up. Risk factors for proctectomy were identified using univariate and multivariate logistic regression analyses. Univariate variables with P < 0.05, which we considered statistically significant, were included in the multivariate analyses. The Fisher’s exact test was used to compare subgroups in patients undergoing reoperation after proctectomy.

Results

All patients

A total of 125 patients with colonic or anorectal CD underwent bowel resection between 2006 and 2016, all of whom we included in our study. Table 1 shows the patient characteristics, while the types of index operations appear in Table 2.
Table 1
Patient descriptive data
Patient characteristics
All cases
Proctectomy
  
No
Yes
Number of patients
125 (100%)
89 (71.2%)
36 (28.8%)
Median age at index operation
39.0 (14.8–74.1)
34.0 (14.8–74.1)
40.5 (22.9–69.4)
Median age at diagnosis
21.8 (3.1–69.9)
22.2 (5.2–69.9)
20.5 (3.1–53.3)
Gender
  Male
66 (52.8%)
54 (60.7%)
12 (33.3%)
  Female
59 (47.2%)
35 (39.3%)
24 (66.7%)
Median duration of CD
12.0 (0–36.8)
9.1 (0–36.8)
16.9 (5.0–32.3)
Median time from index surgery
4.4 (0–10.7)
4.4 (0.3–10.7)
4.6 (0–10.5)
Median time from diagnosis
16.7 (0.5–39.8)
14.8 (0.5–39.8)
19.0 (5.5–38.0)
Preoperative biological medication
43 (34.4%)
34 (38.2%)
9 (25.0%)
Preoperative corticosteroid medication
43 (34.4%)
35 (39.3%)
8 (22.2%)
Preoperative thiopurine medication
98 (78.4%)
77 (86.5%)
21 (58.3%)
History of perianal CD
63 (50.4%)
37 (41.6%)
26 (72.2%)
History of terminal ileum CD
89 (71.2%)
72 (80.9%)
17 (47.2%)
CD Crohn’s disease; values are in years (range) for continuous variables and frequencies (proportion) for categorical variables
Table 2
Types of index operations
Operation
Total
(n = 125)
Small bowel resection
5 (4.0%)
Right colon resection
59 (47.2%)
Left colon resection
15 (12.0%)
Segmental or subtotal colon resection
7 (5.6%)
Colectomy
3 (2.4%)
Proctocolectomy
5 (4.0%)
Proctectomy
31 (24.8%)
At least one previous CD operation was performed on 61 patients (48.8%); 32 patients (25.6%) underwent two or more previous CD operations. Previous CD operations consisted of the following: 15 ileocaecal resections, 12 small bowel resections, 30 segmental colon resections, 7 colectomies with ileorectal anastomosis, 4 colectomies with ileostomy and multiple operations for perianal abscesses and fistulas.
The cumulative rates of proctectomy were 5.6% and 32.0% 10 and 20 years from CD diagnosis, respectively (Fig. 1).
Table 3 shows the risk factors for proctectomy. In the multivariate analysis, CD duration, female gender and perianal CD were independent risk factors for proctectomy. The use of thiopurines was an independent protective factor for proctectomy.
Table 3
Logistic regression analyses of risk factors for proctectomy in surgical Crohn’s colitis patients
 
Univariate analysis
Multivariate analysis
 
Unadjusted
OR (95% CI)
P value
Adjusted
OR (95% CI)
P value
Age at diagnosis
0.984 (0.954–1.015)
0.312
Female gender
3.086 (1.369–6.958)
0.007
3.375 (1.304–8.733)
0.012
Duration of CD
1.084 (1.034–1.136)
0.001
1.067 (1.011–1.126)
0.018
History of perianal CD
3.654 (1.574–8.484)
0.003
3.160 (1.215–8.219)
0.018
Biological medication
0.539 (0.227–1.283)
0.163
Corticosteroid medication
0.441 (0.180–1.077)
0.072
Thiopurine medication
0.218 (0.089–0.536)
0.001
0.170 (0.060–0.486)
0.001
OR odds ratio; CI confidence interval; CD Crohn’s disease; n = 125

Proctectomy patients

A proctectomy was performed on 36 patients (28.8%) at a median of 16.9 years (5.0–32.2 years) from CD diagnosis. The indications for proctectomy are listed in Table 4. Proctectomy was performed by the perineal approach in 3 patients (8.3%), the abdominal approach in 5 patients (13.9%) and the combined abdominoperineal approach in 28 patients (77.8%).
Table 4
Indications for proctectomy
 
Total
(n = 36)
Severe perianal disease
17 (47.2%)
Intensive proctitis
10 (27.7%)
Incontinence
5 (13.9%)
Rectal cancer
2 (5.6%)
Rectal dysplasia
2 (5.6%)
Altogether, 14 patients (38.9%) experienced problems with perineal wound healing. Furthermore, two patients (5.6%) who underwent proctectomy through the abdominal approach only, subsequently required reoperation for the removal of the anus.
After proctectomy, 8 patients (22.2%) required at least 1 reoperation due to recurrent CD. Reoperations consisted of 7 ileal resections performed on 5 patients and 6 colon resections performed on 5 patients.
The reoperation frequency in patients with a history of terminal ileum disease was 29.4% (5 of 17 patients); the frequency in patients without terminal ileum disease was 15.8% (3 of 19 patients, P = 0.28). The reoperation frequency involving only ileal resections was 23.5% (4 of 17 patients) in patients with a history of terminal ileum disease and 5.3% (1 of 19 patients) in patients with no such history (P = 0.14).
The reoperation frequency in patients who underwent proctectomy with end colostomy was 31.6% (6 of 19 patients) and 11.8% (2 of 17 patients) in patients who underwent proctectomy with end ileostomy (P = 0.15).
In the proctectomy group, 20 patients (55.6%) had an end ileostomy, 9 patients (25.0%) had an end transversostomy and 7 patients (19.4%) had an end sigmoideostomy at the end of the follow-up.

Discussion

In our cohort of Crohn’s colitis patients who underwent bowel resection, 28.8% had a proctectomy performed during follow-up. This is comparable with previous studies that described a 19.2 to 25.4% proctectomy rate after colectomy [5, 6, 15]. Our group of patients is more heterogeneous and included patients referred for different bowel resections, but all patients had colonic or anorectal CD.
The proctectomy rate in our study group calculated with the Kaplan-Meier curve was only 5.6% 10 years from CD diagnosis. This low rate can be explained by the fact that some of our patients may not have had colonic involvement at the beginning of disease. Proctectomy risk increases over time, with rates as high as 32% 20 years after CD diagnosis. By contrast, this high rate must be interpreted with caution, since our study included only Crohn’s colitis patients who underwent bowel resection. That is, this patient group may be at higher risk for proctectomy. Previous population-based studies have estimated the rate of definitive stoma as around 14% 20 years after CD diagnosis [16, 17].
We found that the presence of perianal disease is a risk factor for proctectomy, a result also observed by others [16, 18, 19]. In comparison, O’Riordan et al. [6] did not find perianal disease to be a risk factor for proctectomy in their study that included patients who underwent colectomy with ileorectal anastomosis. According to their study, smoking was the only independent risk factor for proctectomy. We could not analyse the influence of smoking in our study, since smoking data at the time of proctectomy was not available.
The risk of perianal disease development in CD patients has been estimated to be as high as 42.7% 20 years after diagnosis [20]. According to that population-based study, perianal disease not only can manifest many years before CD is diagnosed, but can also occur three decades after CD diagnosis. Furthermore, perianal disease is known to be more common in patients with Crohn’s colitis [11, 21, 22].
In our study, female gender was an independent risk factor for proctectomy, a finding consistent with one previous study that concluded that female gender is a risk factor for reoperation following segmental colonic resection for CD [19]. The reason for this remains unclear, but might be due to different attitudes to perianal disease and to permanent stoma between genders.
In addition, the use of thiopurines was an independent protective factor for proctectomy in our study. However, this result should be interpreted with caution since this was a retrospective study. It is possible that patients receiving thiopurines had less aggressive CD and, therefore, did not require proctectomy during follow-up. A meta-analysis of 5 randomized controlled trials showed a 54% improvement of perianal disease in CD patients after thiopurine treatment in contrast to a 21% improvement in the control group [23]. More recently, one randomized controlled trial showed that thiopurines reduced the need for surgery in perianal disease patients [7].
Biological medications are effective in the treatment of perianal disease [810]. Combined anti-tumour necrosis factor-alpha and thiopurine therapy represents the treatment of choice in refractory perianal disease [24]. These studies detected an improvement in perianal disease, but did not specifically evaluate the effect of biological medications in preventing proctectomy.
Coscia et al. [15] compared the risk for permanent stoma surgery before and after the biological medication era. They concluded that the risk for permanent stoma surgery was significantly reduced after the introduction of biological medications. By contrast, a meta-analysis of 556 patients on the requirement for stoma surgery in CD patients concluded that biological medications did not decrease proctectomy rates and only the absence of rectal involvement was significant in the maintenance of bowel continuity [4].
Previous studies have detected a high recurrence rate in Crohn’s colitis in patients with a history of concomitant terminal ileal disease [13, 14]. In our study, these patients also had more reoperations. However, the difference was not significant perhaps due to the small number of patients in the subgroups. Previous studies have also described an increased recurrence rate after end colostomy compared with end ileostomy in Crohn’s colitis patients [11, 12]. The same tendency was observed in our study, although our subgroup analysis did not achieve statistical significance. From a clinical point of view, we would expect disease recurrence in the remaining colon after colostomy. However, it is usually beneficial for the patient to retain some colon as long as possible, even if further operations are needed.
Perineal wound healing problems after proctectomy in CD have been previously described [25, 26]. Yamamoto et al. [25] detected persistent perineal sinuses in 23% of patients who had proctocolectomy. In our study, 38.9% of the patients who underwent proctectomy experienced delayed perineal wound healing. Furthermore, previous perianal CD has been described as a risk factor for perineal wound healing difficulties after proctectomy [26].
Our study has some limitations due to its retrospective design, possibly causing selection bias. We emphasize that our results may not reflect Crohn’s colitis population as a whole, since we only included patients undergoing bowel resection in this study. Patients who did not have proctectomy had a shorter follow-up time from diagnosis than patients with proctectomy. As previously mentioned, patients treated with thiopurines may have had less aggressive CD than those treated with biological medications.
In conclusion, CD duration, female gender and the presence of perianal CD are significant independent risk factors for proctectomy in Crohn’s colitis patients undergoing bowel resection. Further research is necessary to determine if immunosuppressive and biological medications can reduce proctectomy rates in CD patients.

Compliance with ethical standards

All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and comparable ethical standards. For this type of study, formal consent was not required.

Conflict of interest

The authors declare that they have no conflicts of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Lapidus A, Bernell O, Hellers G, Lofberg R (1998) Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology 114:1151–1160CrossRefPubMed Lapidus A, Bernell O, Hellers G, Lofberg R (1998) Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology 114:1151–1160CrossRefPubMed
2.
Zurück zum Zitat Andersson P, Olaison G, Hallbook O, Sjodahl R (2002) Segmental resection or subtotal colectomy in Crohn’s colitis? Dis Colon Rectum 45:47–53CrossRefPubMed Andersson P, Olaison G, Hallbook O, Sjodahl R (2002) Segmental resection or subtotal colectomy in Crohn’s colitis? Dis Colon Rectum 45:47–53CrossRefPubMed
4.
Zurück zum Zitat Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV Jr (2015) Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42:783–792CrossRefPubMedPubMedCentral Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV Jr (2015) Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42:783–792CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Longo WE, Oakley JR, Lavery IC, Church JM, Fazio VW (1992) Outcome of ileorectal anastomosis for Crohn’s colitis. Dis Colon Rectum 35:1066–1071CrossRefPubMed Longo WE, Oakley JR, Lavery IC, Church JM, Fazio VW (1992) Outcome of ileorectal anastomosis for Crohn’s colitis. Dis Colon Rectum 35:1066–1071CrossRefPubMed
6.
Zurück zum Zitat O’Riordan JM, O’Connor BI, Huang H, Victor JC, Gryfe R, MacRae HM, Cohen Z, McLeod RS (2011) Long-term outcome of colectomy and ileorectal anastomosis for Crohn’s colitis. Dis Colon Rectum 54:1347–1354CrossRefPubMed O’Riordan JM, O’Connor BI, Huang H, Victor JC, Gryfe R, MacRae HM, Cohen Z, McLeod RS (2011) Long-term outcome of colectomy and ileorectal anastomosis for Crohn’s colitis. Dis Colon Rectum 54:1347–1354CrossRefPubMed
7.
Zurück zum Zitat Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF, Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube D (2013) Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 145:758–765 e752; quiz e714–755CrossRefPubMed Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF, Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube D (2013) Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 145:758–765 e752; quiz e714–755CrossRefPubMed
8.
Zurück zum Zitat Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405CrossRefPubMed Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405CrossRefPubMed
9.
Zurück zum Zitat Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885CrossRefPubMed Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885CrossRefPubMed
10.
Zurück zum Zitat Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32:1228–1239CrossRefPubMed Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32:1228–1239CrossRefPubMed
11.
Zurück zum Zitat de Buck van Overstraeten A, Wolthuis AM, Vermeire S, Van Assche G, Rutgeerts P, Penninckx F, D’Hoore A (2013) Intersphincteric proctectomy with end-colostomy for anorectal Crohn’s disease results in early and severe proximal colonic recurrence. J Crohns Colitis 7:e227–e231CrossRefPubMed de Buck van Overstraeten A, Wolthuis AM, Vermeire S, Van Assche G, Rutgeerts P, Penninckx F, D’Hoore A (2013) Intersphincteric proctectomy with end-colostomy for anorectal Crohn’s disease results in early and severe proximal colonic recurrence. J Crohns Colitis 7:e227–e231CrossRefPubMed
12.
Zurück zum Zitat Koriche D, Gower-Rousseau C, Chater C, Duhamel A, Salleron J, Tavernier N, Colombel JF, Pariente B, Cortot A, Zerbib P (2017) Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Colorectal Dis 32:453–458CrossRefPubMed Koriche D, Gower-Rousseau C, Chater C, Duhamel A, Salleron J, Tavernier N, Colombel JF, Pariente B, Cortot A, Zerbib P (2017) Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Colorectal Dis 32:453–458CrossRefPubMed
13.
Zurück zum Zitat Lock MR, Fazio VW, Farmer RG, Jagelman DG, Lavery IC, Weakley FL (1981) Proximal recurrence and the fate of the rectum following excisional surgery for Crohn’s disease of the large bowel. Ann Surg 194:754–760CrossRefPubMedPubMedCentral Lock MR, Fazio VW, Farmer RG, Jagelman DG, Lavery IC, Weakley FL (1981) Proximal recurrence and the fate of the rectum following excisional surgery for Crohn’s disease of the large bowel. Ann Surg 194:754–760CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cattan P, Bonhomme N, Panis Y, Lemann M, Coffin B, Bouhnik Y, Allez M, Sarfati E, Valleur P (2002) Fate of the rectum in patients undergoing total colectomy for Crohn’s disease. Br J Surg 89:454–459CrossRefPubMed Cattan P, Bonhomme N, Panis Y, Lemann M, Coffin B, Bouhnik Y, Allez M, Sarfati E, Valleur P (2002) Fate of the rectum in patients undergoing total colectomy for Crohn’s disease. Br J Surg 89:454–459CrossRefPubMed
15.
Zurück zum Zitat Coscia M, Gentilini L, Laureti S, Gionchetti P, Rizzello F, Campieri M, Calabrese C, Poggioli G (2013) Risk of permanent stoma in extensive Crohn’s colitis: the impact of biological drugs. Colorectal Dis 15:1115–1122PubMed Coscia M, Gentilini L, Laureti S, Gionchetti P, Rizzello F, Campieri M, Calabrese C, Poggioli G (2013) Risk of permanent stoma in extensive Crohn’s colitis: the impact of biological drugs. Colorectal Dis 15:1115–1122PubMed
16.
Zurück zum Zitat Post S, Herfarth C, Schumacher H, Golling M, Schurmann G, Timmermanns G (1995) Experience with ileostomy and colostomy in Crohn’s disease. Br J Surg 82:1629–1633CrossRefPubMed Post S, Herfarth C, Schumacher H, Golling M, Schurmann G, Timmermanns G (1995) Experience with ileostomy and colostomy in Crohn’s disease. Br J Surg 82:1629–1633CrossRefPubMed
17.
Zurück zum Zitat Etienney I, Bouhnik Y, Gendre JP, Lemann M, Cosnes J, Matuchansky C, Beaugerie L, Modigliani R, Rambaud JC (2004) Crohn’s disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol 28:1233–1239CrossRefPubMed Etienney I, Bouhnik Y, Gendre JP, Lemann M, Cosnes J, Matuchansky C, Beaugerie L, Modigliani R, Rambaud JC (2004) Crohn’s disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol 28:1233–1239CrossRefPubMed
18.
Zurück zum Zitat Kiran RP, Nisar PJ, Church JM, Fazio VW (2011) The role of primary surgical procedure in maintaining intestinal continuity for patients with Crohn’s colitis. Ann Surg 253:1130–1135CrossRefPubMed Kiran RP, Nisar PJ, Church JM, Fazio VW (2011) The role of primary surgical procedure in maintaining intestinal continuity for patients with Crohn’s colitis. Ann Surg 253:1130–1135CrossRefPubMed
19.
Zurück zum Zitat Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA (2005) Recurrence after segmental resection for colonic Crohn’s disease. Br J Surg 92:1143–1149CrossRefPubMed Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA (2005) Recurrence after segmental resection for colonic Crohn’s disease. Br J Surg 92:1143–1149CrossRefPubMed
20.
Zurück zum Zitat Eglinton TW, Barclay ML, Gearry RB, Frizelle FA (2012) The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 55:773–777CrossRefPubMed Eglinton TW, Barclay ML, Gearry RB, Frizelle FA (2012) The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 55:773–777CrossRefPubMed
21.
Zurück zum Zitat Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ (2002) The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122:875–880CrossRefPubMed Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ (2002) The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122:875–880CrossRefPubMed
23.
Zurück zum Zitat Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142CrossRefPubMed Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142CrossRefPubMed
24.
Zurück zum Zitat Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, Group SS (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395CrossRef Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, Group SS (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395CrossRef
25.
Zurück zum Zitat Yamamoto T, Keighley MR (2000) Fate of the rectum and ileal recurrence rates after total colectomy for Crohn’s disease. World J Surg 24:125–129CrossRefPubMed Yamamoto T, Keighley MR (2000) Fate of the rectum and ileal recurrence rates after total colectomy for Crohn’s disease. World J Surg 24:125–129CrossRefPubMed
Metadaten
Titel
Risk factors for proctectomy in consecutive Crohn’s colitis surgical patients in a reference colorectal centre
verfasst von
Gisele Aaltonen
Monika Carpelan-Holmström
Ilona Keränen
Anna Lepistö
Publikationsdatum
28.06.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 8/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03337-8

Weitere Artikel der Ausgabe 8/2019

International Journal of Colorectal Disease 8/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.